Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014:2014:842452.
doi: 10.1155/2014/842452. Epub 2014 Mar 5.

Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients

Alexander Hein  1 , Christian M Bayer  1 , Michael G Schrauder  1 , Lothar Häberle  1 , Katharina Heusinger  1 , Reiner Strick  1 , Matthias Ruebner  1 , Michael P Lux  1 , Stefan P Renner  1 , Rüdiger Schulz-Wendtland  2 , Arif B Ekici  3 , Arndt Hartmann  4 , Matthias W Beckmann  1 , Peter A Fasching  1
Affiliations
Clinical Trial

Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients

Alexander Hein et al. Biomed Res Int. 2014.

Abstract

The receptor activator of NF-κB (RANK) pathway is involved in bone health as well as breast cancer (BC) pathogenesis and progression. Whereas the therapeutic implication of this pathway is established for the treatment of osteoporosis and bone metastases, the application in adjuvant BC is currently investigated. As genetic variants in this pathway have been described to influence bone health, aim of this study was the prognostic relevance of genetic variants in RANK and RANKL. Single nucleotide polymorphisms in RANK(L) (rs1054016/rs1805034/rs35211496) were genotyped and analyzed with regard to bone metastasis-free survival (BMFS), disease-free survival, and overall survival for a retrospective cohort of 1251 patients. Cox proportional hazard models were built to examine the prognostic influence in addition to commonly established prognostic factors. The SNP rs1054016 seems to influence BMFS. Patients with two minor alleles had a more favorable prognosis than patients with at least one common allele (HR 0.37 (95% CI: 0.17, 0.84)), whereas other outcome parameters remained unaffected. rs1805034 and rs35211496 had no prognostic relevance. The effect of rs1054016(RANKL) adds to the evidence that the RANK pathway plays a role in BC pathogenesis and progression with respect to BMFS, emphasizing the connection between BC and bone health.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curves for rs1054016 and bone metastasis-free survival according to genotypes.
Figure 2
Figure 2
Kaplan-Meier curves for rs1054016 and progression-free survival according to genotypes.
Figure 3
Figure 3
Kaplan-Meier curves for rs1054016 and overall survival according to genotypes.
See this image and copyright information in PMC

References

    1. Coleman R, Gnant M, Paterson A, et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. Proceedings of the San Antonio Breast Cancer Symposium; 2013; pp. S4–S7.
    1. Juhasz-Boss I, Fehm T, Ney JT, et al. Pathophysiology of bone remodelling and current therapeutic approaches. Geburtsh Frauenheilk. 2012;72(6):502–506. - PMC - PubMed
    1. Asselin-Labat M-L, Vaillant F, Sheridan JM, et al. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010;465(7299):798–802. - PubMed
    1. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103–107. - PubMed
    1. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440(7084):692–696. - PubMed

Publication types

Substances